Neurocrine Biosciences (NBIX) Stock Chart - Revenue & Earnings | Quarter Chart
Revenue by Product
Revenue by Geography
Revenue, Gross Profit, Operating and Net Income
Margin (%)
Operating Expenses
EBITDA
EPS
Revenue Variation (%)
Income Variation (%)
Revenue YoY Variation (%)
Income YoY Variation (%)
Price-to-Earning Ratio
Income Breakdown
Per Share Metrics
Expense Ratios
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt Ratio
Current Ratio
Quick Ratio
Cash & Equivalents
Total Assets
Total Liabilities
Shareholders Equity
Asset Composition
Debt Structure
Neurocrine Biosciences (NBIX) quarterly earnings & revenue
Neurocrine Biosciences (NBIX) reported revenue of $814.50M for Q1 2026, up 42.2% year-over-year, with net income of $197.90M and diluted EPS of $1.91.
Over the last four reported quarters, Neurocrine Biosciences generated $3.10B in revenue and $668.60M in net income.
Neurocrine Biosciences's next earnings report is scheduled for July 30, 2026; analysts estimate EPS of $2.19.
Neurocrine Biosciences quarterly results
| Fiscal quarter | Revenue | Revenue YoY | Net income | EPS (diluted) |
|---|---|---|---|---|
| Q1 2026 | $814.50M | +42.2% | $197.90M | $1.91 |
| Q4 2025 | $805.50M | +28.3% | $153.70M | $1.48 |
| Q3 2025 | $794.90M | +27.8% | $209.50M | $2.04 |
| Q2 2025 | $687.50M | +16.5% | $107.50M | $1.06 |
| Q1 2025 | $572.60M | +11.1% | $7.90M | $0.08 |
| Q4 2024 | $627.70M | +21.8% | $103.10M | $1.00 |
| Q3 2024 | $622.10M | +24.7% | $129.80M | $1.24 |
| Q2 2024 | $590.20M | +30.4% | $65.00M | $0.63 |
Neurocrine Biosciences (NBIX) — frequently asked questions
When does Neurocrine Biosciences (NBIX) report earnings next?
Neurocrine Biosciences is expected to report earnings on July 30, 2026. Analysts estimate EPS of $2.19.
What was NBIX's revenue last quarter?
Neurocrine Biosciences reported revenue of $814.50M in Q1 2026, up 42.2% from the same quarter a year earlier.
What was NBIX's EPS last quarter?
Neurocrine Biosciences reported diluted EPS of $1.91 in Q1 2026.
Is Neurocrine Biosciences profitable?
Neurocrine Biosciences is currently profitable, with $668.60M in net income over the last four reported quarters.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Roche (ROG.SW) · Merck (MRK)